Drug intelligence / Profile preview

PCV21

Development stage: Approved
Lead developer: Sanofi
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PCV21 is an investigational 21-valent pneumococcal conjugate vaccine developed through a collaboration between Sanofi and SK bioscience. It is designed to induce the body to produce antibodies against *Streptococcus pneumoniae* serotypes, aiming to provide broader protection against invasive pneumococcal disease than current vaccines. Sanofi is responsible for global commercialization outside South Korea, while SK bioscience holds exclusivity in South Korea and contributes its vaccine technology and manufacturing expertise.

Brand names: Capvaxive
Other names: 21-valent Pneumococcal Conjugate Vaccineinvestigational pneumococcal conjugate vaccine

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on PCV21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCV21.

Explore the full profile